CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced data today from ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

SOUTH SAN FRANCISCO, Calif., December 08, 2025--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic ...

Human factors (also referred to as human factors psychology and human factors engineering) is an applied field of study that examines human abilities, limitations, behaviors, and processes in order to ...

Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to their critical treatment, paving the way for the development of more effective ...

Medically reviewed by Doru Paul, MD Key Takeaways Hemophilia A is a bleeding disorder caused by a deficiency in factor VIII. Treatment options for hemophilia A include replacing factor VIII and gene ...

Healio spoke with an expert hematologist about treatments that impact factor VIII deficiency in hemophilia A and von Willebrand disease as well as advancements and greatest areas of unmet need in the ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase ...